Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): An international, open-label, phase 2 trial

A phase II trial evaluated the efficacy of afamitresgene autoleucel for the treatment of patients with HLA-A*02 and MAGE-A4–expressing advanced synovial sarcoma or myxoid round cell liposarcoma. The researchers found durable responses in this heavily pretreated patient population. These data show promise for the use of T-cell receptor therapy to target solid tumors and highlight the need for further investigation in this disease space. This study led to the recent U.S. Food and Drug Administration-accelerated approval for afamitresgene autoleucel for adults with unresectable or metastatic synovial sarcoma.